BAXTER: PHASE I TRIAL OF LONGER-ACTING RECOMBINANT FVIII

Link to Baxter’s Press ReleaseBAXTER INITIATES PHASE I CLINICAL TRIAL OF LONGER-ACTING RECOMBINANT FVIII TREATMENT FOR HEMOPHILIA AInvestigational BAX 855 is based on ADVATE Factor VIII MoleculeDEERFIELD, Ill., January 5, 2012 – Baxter International Inc. today announced the dosing of the first patients in a Phase I clinical trial of its lead investigational candidate, BAX […]